35 results about "Germline mutation" patented technology

The invention relates to an intelligent tumor medication instruction system. The intelligent tumor medication instruction system is characterized by comprising a patient information module, a gene mutation detection module, a medication instruction database and a detection result reporting module, wherein the patient information module is used for recording the basic information of a patient; the gene mutation detection module is used for detecting the gene mutation information of the patient, such as a gene name, a mutation site, mutation conditions, mutation frequency and germline mutation and / or somatic cell mutation; the medication instruction database is used for performing medication instruction and query according to the clinical information of the patient, automatically matching and sequencing the clinical information and the medication instruction and query results, and sending an optimum medication instruction scheme suitable for the tumor patient to the detection result reporting module; a doctor can instruct the medication on the tumor patient according to the medication scheme displayed by the detection result reporting module. The intelligent tumor medication instruction system is widely applied to the diagnosis and medication instruction process of the tumor patient.

The present disclosure provides a probabilistic model for accurate and sensitive somatic single nucleotide variant (SNV) detection in cell-free nucleic acid samples comprising a set of sequence data.A joint genotype may be determined for each locus in the set of sequence data, and germline mutations may be intrinsically removed. A set of filtrations can be applied to eliminate low quality somaticvariant calls. Further, a global tumor cell-free deoxyribonucleic acid (cfDNA) fraction and overlapping read mates can be considered, thereby enabling accurate SNV detection and variant allele frequency estimation from samples with low tumor cfDNA fraction. A sensitive early detection of minimal residual disease (MRD) is designed by using the probabilistic model and the machine learning model fordistinguishing true variants from sequencing errors.

The present invention relates to methods and kits for determining a predisposition for developing cancer, e.g., prostate and / or breast cancer, due to a germline mutation of a NBS1 gene. The present invention also relates to surveillance protocols for developing cancer, e.g., prostate and / or breast cancer, due to germline mutation of a NBS1 gene.

The invention relates to a method for distinguishing gene mutation types an individual tumor sample based on second-generation sequencing. A tumor tissue sample and a normal tissue sample are used forlibrary construction and NGS sequencing respectively, strand bias and different types of base frequencies of mutation sites stored in an intermediate file BAM for biological information analysis of the tumor tissue sample are analyzed, the quality of base comparison and the frequency of noise are used as the training characteristics of machine learning, meanwhile, type information of corresponding mutation sites of the normal tissue sample is paired to serve as a prediction mutation type, a classification prediction model is constructed to distinguish somatic mutation from germline mutation,the model is used to distinguish somatic mutation from germline mutation, the detection efficiency is high, the specificity is high, and after the model is established, the individual tumor sample canbe used for NGS sequencing and mutation detection, the detection cost of a normal or cancer sample can be well saved, and meanwhile, the problem that normal tissues of tumor patients with specific types are difficult to obtain can be solved.

The present invention relates to methods and kits for determining a predisposition for developing cancer, e.g., prostate and / or breast cancer, due to a germline mutation of a NBS1 gene. The present invention also relates to surveillance protocols for developing cancer, e.g., prostate and / or breast cancer, due to germline mutation of a NBS1 gene.

The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human obesity and diabetes predisposing gene, specifically the TBC1D1 gene, some mutant alleles of which cause susceptibility to obesity and / or diabetes. More specifically, the invention relates to germline mutations in the TBC1D1 gene and their use in the diagnosis of predisposition to obesity and diabetes. Finally, the invention relates to the screening of the TBC1D1 gene for mutations / alterations, which are useful for diagnosing the predisposition to obesity.

The present invention relates generally to the field of human genetics, and more specifically to the detection of a specific type of germline mutations in the BRCA1 gene, which will predispose to breast and ovarian cancer. In addition, the invention relates to the molecular genetic mechanism that may have mediated the genesis of these mutations, in particular the role of Alu repetitive DNA elements present in the intronic regions of BRCA1. The invention further relates to somatic mutations of this type in the BRCA1 gene in human breast and ovarian cancer, and their use in the diagnosis and prognosis of human breast and ovarian cancer. The invention more particularly relates to the screening of this type of BRCA1 mutations in human genomic DNA, which are useful for the diagnosis of inherited predisposition to breast and ovarian cancer.

The present invention discloses a MED12 gene mutation detecting kit and an application thereof. The kit comprises probe sets for detecting MED12 gene mutations and the probe sets consist of a probe 1to a probe 48. The kit can be used for detecting MED12 somatic mutations and germline mutations at a tumor genome level, can also be used for assistant diagnosis and minimal residual disease monitoring and prognosis evaluation, etc. of patients with hematological tumors, especially patients with acute myeloid leukemia. Besides, the kit is simple, sensitive and accurate in detection method and plays an important role in the field of medical detection

The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human depression predisposing gene, specifically the apoptotic protease activating factor 1 (APAF1) gene, some mutant alleles of which cause susceptibility to depression. More specifically, the invention relates to germline mutations in the APAF1 gene and their use in the diagnosis of predisposition to depression. The invention also relates to the prophylaxis and / or therapy of depression associated with a mutation in the APAF1 gene. The invention further relates to the screening of drugs for depression therapy. Finally, the invention relates to the screening of the APAF1 gene for mutations / alterations, which are useful for diagnosing the predisposition to depression.

The invention relates to an identification method of the high stoichiometric ratio non-germline mutation in the eucaryotic cell and provides an semi-quantitative identification method of the protein synthesis error caused by the single amino acid mutation of the non-germline mutation (NGM), wherein the method is based on the proteomics technology and genome DNA sequencing of the mass spectrometry. The method is particularly as follows: the large-scale proteome analysis, the unrestricted sequence alignment and the identification and gene sequencing of the high resolution second-order mass spectrum and third-order mass spectrum of the synthetic peptide segment are integrated to perform systematic synthesis to the NGM and identify that the four peptide segments of four proteins contain the NGMs. By adopting the method for estimation, the NGM occurrence in the peptide segment is about 0.05%, which is more than 0.3% on the protein level. According to the peptide mass spectrum count ratio of mutant peptide segments to normal peptide segments, the stoichiometric ratio of the NGM is 0.05 to 0.71. By adopting the identification method, the NGM is proved to have high occurrence and stoichiometric ratio while the NGM is predicted to be used as a possible mechanism to join the basic biological and physiological processes.

The invention provides a series of steps that prepare nucleic acids (RNA and / or DNA) isolated from extracellular vesicles for sequencing. This enables a wide diversity of RNAs and / or DNAs, to be efficiently detected. These can then be used to identify various attributes such as gene expression, alternative splicing, and the detection of both somatic and germline mutations including single nucleotide variants (SNV) and structural variations (insertions / deletions, fusions, inversions).

The present invention relates generally to the field of human genetics, and more specifically to the detection of a specific type of germline mutations in the BRCA1 gene, which will predispose to breast and ovarian cancer. In addition, the invention relates to the molecular genetic mechanism that may have mediated the genesis of these mutations, in particular the role of Alu repetitive DNA elements present in the intronic regions of BRCA1. The invention further relates to somatic mutations of this type in the BRCA1 gene in human breast and ovarian cancer, and their use in the diagnosis and prognosis of human breast and ovarian cancer. The invention more particularly relates to the screening of this type of BRCA1 mutations in human genomic DNA, which are useful for the diagnosis of inherited predisposition to breast and ovarian cancer.

The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect human diabetes mellitus predisposing gene, specifically the angiotensinogen (AGT) gene, some mutant alleles of which cause susceptibility to insulin-dependent diabetes mellitus (IDDM). More specifically, the invention relates to germline mutations in the AGT gene and their use in the diagnosis of predisposition to diabetes. The invention also relates to the prophylaxis and / or therapy of diabetes associated with a mutation in the AGT gene. The invention further relates to the screening of drugs for diabetes therapy. Finally, the invention relates to the screening of the AGT gene for mutations, which are useful for diagnosing the predisposition to diabetes.

The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to detect a human sporadic DCM predisposing gene, specifically the dystrophin gene, some mutant alleles of which cause susceptibility to sporadic DCM. More specifically, the invention relates to germline mutations in the dystrophin gene and their use in the diagnosis of predisposition to sporadic DCM. The invention also relates to the prophylaxis and / or therapy of sporadic DCM associated with a mutation in the dystrophin gene. The invention further relates to the screening of drugs for sporadic DCM therapy. Finally, the invention relates to the screening of the dystrophin gene for mutations / alterations, which are useful for diagnosing the predisposition to sporadic DCM.

The invention relates to a method for distinguishing a somatic mutation and a germline mutation. The method comprises the following steps of obtaining at least one mutation site from a subject sample; obtaining a wild type support fragment and a mutant type support fragment, wherein the wild type support fragment is a cfDNA fragment containing a wild type base sequence, the mutant type support fragment is a cfDNA fragment containing a mutant type base sequence, the wild type base sequence is the same as a nucleotide sequence of a human reference genome at a corresponding position of a mutation site, and the mutant type base sequence is different; obtaining the number of the wild type support fragments with at least one length, obtaining the number of the corresponding mutant type support fragments with the same length, and calculating the difference value between the ratio of the wild type support fragments with the same length to the total number of the corresponding support fragments and the the ratio of the mutant type support fragments with the same length to the total number of the corresponding support fragments ; and taking the difference value as a distinguishing index. Method and device for identifying ctDNA from cfDNA are provided. The method is used for tumor family management and TMB detection.

The present invention discloses a kit for simultaneously detecting mutations of genes NBPF10, TSFM, PRB2 and DIAPH1, wherein the kit comprises a plurality of multi-gene capture probes, can be used fordetecting the somatic mutations and the germline mutations at the tumor genome level, can be used for the assisted diagnosis of patients with hematological tumors (especially acute lymphoblastic leukemia patients), the monitoring of minimal residual diseases, the evaluation of prognosis, and the like, and can provide important effect in the field of medical detection, wherein the detection methodis simple and sensitive.

The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human obesity and diabetes predisposing gene, specifically the TBC1D1 gene, some mutant alleles of which cause susceptibility to obesity and / or diabetes. More specifically, the invention relates to germline mutations in the TBC1D1 gene and their use in the diagnosis of predisposition to obesity and diabetes. Finally, the invention relates to the screening of the TBC1D1 gene for mutations / alterations, which are useful for diagnosing the predisposition to obesity.

A method of providing a diagnosis for a subject having Cowden-like syndrome or PTEN germline mutations is described. The method includes the steps of: (a) obtaining a biological sample from a subject; (b) conducting a germline PTEN mutation and deletion analysis of genomic DNA from the biological sample; (c) determining the level of copy number variation in the genomic DNA; (d) comparing the level of copy number variation in the genomic DNA to a control value for copy number variation; and (e) diagnosing the subject as having an increased risk of developing a neurodevelopmental disorder if the copy number variation level is higher than the control value.

The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human depression predisposing gene, specifically the apoptotic protease activating factor 1 (APAF1) gene, some mutant alleles of which cause susceptibility to depression. More specifically, the invention relates to germline mutations in the APAF1 gene and their use in the diagnosis of predisposition to depression. The invention also relates to the prophylaxis and / or therapy of depression associated with a mutation in the APAF1 gene. The invention further relates to the screening of drugs for depression therapy. Finally, the invention relates to the screening of the APAF1 gene for mutations / alterations, which are useful for diagnosing the predisposition to depression.

The invention discloses a thalassemia mutant gene detection primer composition. The thalassemia mutant gene detection primer composition comprises 131 pairs of first primers; each pair of first primers comprises a forward primer and a reverse primer, and each of the forward primer and the reverse primer comprises an amplification primer pair and other sequences connected with the 5' end of the amplification primer pair; the specific sequence of each pair of forward primer and reverse primer is selected from the sequences as shown in SEQ ID NO.1 to 262. According to the invention, three germline mutation related genes, namely HBA1 / 2 and HBB, which are important to thalassemia, are selected, not only can common SNV and short indel be detected, but also complex CNV mutation can be detected, and through peripheral blood gDNA detection, on one hand, genetic diagnosis of alpha and / or beta thalassemia can be carried out on suspected thalassemia patients, and on the other hand, genetic evaluation can be carried out on high-risk couples with thalassemia, and prenatal genetic diagnosis can be carried out on fetuses.

The invention relates to a combined detection method for lymphangioleiomyomatosis and its application, and belongs to the technical field of gene detection. The method includes the following steps: liquid phase capture targeted sequencing: Panel design for the whole-exon coding regions of TSC1 and TSC2 genes highly related to LAM and mutant genes closely related to solid tumors, construction of gDNA library, and after hybridization capture, On-machine sequencing; sorting: analyze the above sequencing data by bioinformatics processing, if the TSC1 and TSC2 genes are detected negative, the chromosome chip analysis method is used for supplementary detection; if the single hit site is detected, the multiple ligation probe is used Amplification is used for supplementary testing; if loci with unclear somatic mutation and germline mutation origin are detected, Sanger test is used for supplementary testing. This method improves the detection rate of positive variants in LAM patients.

The present invention provides the use of TMEM236 gene in preparing a marker for diagnosing locally advanced rectal cancer neoadjuvant radiotherapy primary resistance. The TMEM236 gene mutation site is chr10:17796115. If it is detected that the TMEM236 gene is at the site The point mutation of chr10:17796115, TMEM236:NM_001098844:exon4:c.G667A, shows that the patient is resistant to radiotherapy. The present invention also provides the use of the kit for detecting TMEM236 gene mutation in the preparation of a neoadjuvant radiotherapy resistance diagnostic composition for diagnosing locally advanced rectal cancer. The germline mutation mutant gene TMEM236 screened by the invention can be used for predicting the primary resistance of patients with locally advanced rectal cancer to neoadjuvant radiotherapy.

The invention provides a method and device for detecting TMB. The method comprises: using the sequencing data of paired white blood cells to remove the germline mutation sites in the sequencing data of the sample to be tested to obtain a set of candidate somatic mutation sites; filtering false positive somatic mutation sites in the set of candidate somatic mutation sites to obtain The set of somatic mutation sites to be detected, the false positive somatic mutation sites include at least one of the following: mutation sites caused by oxidative damage, mutation sites caused by background noise; load mutations that concentrate the somatic mutation sites to be detected The number is divided by all the lengths of the sequencing data in the exon region to obtain the TMB. The accuracy and stability of TMB are improved by making full use of paired leukocytes, background noise mutation frequency distribution database, and oxidative damage to remove false positive somatic mutations.

The invention relates to a method for distinguishing gene mutation types an individual tumor sample based on second-generation sequencing. A tumor tissue sample and a normal tissue sample are used forlibrary construction and NGS sequencing respectively, strand bias and different types of base frequencies of mutation sites stored in an intermediate file BAM for biological information analysis of the tumor tissue sample are analyzed, the quality of base comparison and the frequency of noise are used as the training characteristics of machine learning, meanwhile, type information of corresponding mutation sites of the normal tissue sample is paired to serve as a prediction mutation type, a classification prediction model is constructed to distinguish somatic mutation from germline mutation,the model is used to distinguish somatic mutation from germline mutation, the detection efficiency is high, the specificity is high, and after the model is established, the individual tumor sample canbe used for NGS sequencing and mutation detection, the detection cost of a normal or cancer sample can be well saved, and meanwhile, the problem that normal tissues of tumor patients with specific types are difficult to obtain can be solved.

The invention provides a series of steps that prepare nucleic acids (RNA and / or DNA) isolated from extracellular vesicles for sequencing. This enables a wide diversity of RNAs and / or DNAs, to be efficiently detected. These can then be used to identify various attributes such as gene expression, alternative splicing, and the detection of both somatic and germline mutations including single nucleotide variants (SNV) and structural variations (insertions / deletions, fusions, inversions).

The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human obesity and diabetes predisposing gene, specifically the TBC1D1 gene, some mutant alleles of which cause susceptibility to obesity and / or diabetes. More specifically, the invention relates to germline mutations in the TBC1D1 gene and their use in the diagnosis of predisposition to obesity and diabetes. Finally, the invention relates to the screening of the TBC1D1 gene for mutations / alterations, which are useful for diagnosing the predisposition to obesity.

A diagnostic strategy for detection of inherited diseases caused by germline mutations is based on somatic cell hybridization. Each allele of a human gene involved in the inherited disease is isolated in a somatic cell hybrid. The products of the isolated human allele are then observed in the absence of the other allele of the human.